Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 1/20 | 0.33 |
| ▸ | SYK | P43405 | 6/20 | 0.32 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.31 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.31 |
| ▸ | CCR5 | P51681 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17097955 | 1.00 | TACR1 (0.33) | TACR1SYKNPY5RNTRK1CCR5 | |
| SCHEMBL17098744 | 0.92 | HSD11B1 (0.31) | NPY5RHSD11B1 | |
| SCHEMBL17098741 | 0.92 | HSD11B1 (0.31) | NPY5RHSD11B1 | |
| SCHEMBL17098417 | 0.89 | HSD11B1 (0.32) | NTRK1ALDH1A1MAPTHSD11B1MEN1 | |
| SCHEMBL17098418 | 0.89 | HSD11B1 (0.32) | NTRK1ALDH1A1MAPTHSD11B1MEN1 | |
| SCHEMBL17097469 | 0.88 | SMN1; SMN2 (0.31) | ALDH1A1MAPTHSD11B1MEN1KMT2A | |
| SCHEMBL17097471 | 0.88 | SMN1; SMN2 (0.31) | ALDH1A1MAPTHSD11B1MEN1KMT2A | |
| SCHEMBL17048750 | 0.87 | SLC6A9 (0.31) | — | |
| SCHEMBL17048738 | 0.87 | HSD11B1 (0.31) | HSD11B1 | |
| SCHEMBL17098317 | 0.87 | HSD11B1 (0.31) | HSD11B1MEN1KMT2ANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9365522-B2 | Pyrazole amide derivative | AMGEN INC. (US) | 2016-06-14 | — | — | US | claimed |
| US-20150266824-A1 | Pyrazole Amide Derivative | TEIJIN LIMITED (JP) | 2015-09-24 | — | — | US | claimed |
| EP-3110810-B1 | PYRAZOLE AMIDE DERIVATIVE | TEIJIN PHARMA LTD (JP) | 2018-05-02 | — | — | EP | disclosed |
| US-9365522-B2 | Pyrazole amide derivative | AMGEN INC. (US) | 2016-06-14 | — | — | US | disclosed |
| US-20150266824-A1 | Pyrazole Amide Derivative | TEIJIN LIMITED (JP) | 2015-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150266824-A1 | Pyrazole Amide Derivative | RORC, RORB, RORA | TACR1 3660/4885SYK 2147/4885NPY5R 471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.